DBV Technologies announced that the Food and Drug Administration (FDA) has lifted the partial clinical hold from a Phase 3 clinical trial for Viaskin™ Peanut. A “partial clinical hold” is a delay or a suspension of part of a clinical study. Viaskin Peanut (a skin patch) is a novel treatment being tested for peanut allergy treatment. Phase 3 of VITESSE, the Viaskin Peanut Immunotherapy Trial To Evaluate Safety Simplicity, Efficacy and Effectiveness, is designed to examine the modified…
